Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
ROCKVILLE, Md., Nov. 08, 2017 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update for the Company, and host investor meetings at the following three conferences:
Stifel 2017 Healthcare Conference
Date: Tuesday, November 14, 2017
Time: 11:45 a.m. EST
Place: Lotte New York Palace Hotel, New York
Jefferies 2017 London Healthcare Conference
Date: Thursday, November 16, 2017
Time: 4:40 p.m. GMT (11:40 a.m. EST)
Place: Waldorf Hilton, London, U.K.
Piper Jaffray 29th Annual Healthcare Conference
Date: Wednesday, November 29, 2017
Time: 8:00 a.m. EST
Place: Lotte New York Palace Hotel, New York
Investors interested in arranging a meeting with the Company's management during these conferences should contact the conference coordinator.
A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website at www.supernus.com. An archived replay of these webcasts will be available for 60 days on the Company's website after each conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.
CONTACT:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: [email protected]
